Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gene therapy rising: Bluebird soars at ASH, Pfizer builds platform

This article was originally published in Scrip

Executive Summary

With the potential to cure debilitating diseases, gene therapy has become a darling of the biotechnology industry. The latest evidence: Bluebird Bio's 8 December after-hours stock market rise by 43.2% to $70 per share on data from four transfusion-free beta-thalassemia patients and Pfizer's investment in a gene therapy platform that includes a hemophilia B collaboration with Spark Therapeutics.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts